Oncobit

Oncobit AG, founded in 2018 as a spin-off from the University of Zurich, is dedicated to developing a scalable, data-driven cancer monitoring platform based on the quantitative and highly sensitive detection of cancer markers in liquid biopsies. By focusing on the most clinically relevant biomarkers and leveraging cutting-edge technology, the company provides cost-effective and time-saving solutions, enabling close monitoring of patients' cancer conditions and supporting optimized treatment management. Its cloud-based analysis and interpretation software, trained on datasets from healthy individuals and patients, ensures reliable and standardized reporting of results.